Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405524 | 0.82 | CYP1A2 (0.46) | CYP1A2KMT2ANCF1 | |
| SCHEMBL3967744 | 0.81 | NPC1 (0.44) | ERBB2SMN1; SMN2CYP1A2KDM4EMEN1 | |
| SCHEMBL4048580 | 0.77 | CYP1A2 (0.41) | ERBB2SMN1; SMN2HTTCYP1A2KDM4E | |
| SCHEMBL3969617 | 0.72 | CYP1A2 (0.41) | SMN1; SMN2HTTCYP1A2KDM4EMEN1 | |
| SCHEMBL3969618 | 0.72 | NCF1 (0.49) | SMN1; SMN2HTTCYP1A2KDM4EMEN1 | |
| SCHEMBL3964963 | 0.72 | CYP1A2 (0.50) | SMN1; SMN2PKMMAPK1RXFP1HTT | |
| SCHEMBL6598929 | 0.72 | PPARG (0.49) | SMN1; SMN2PKMKDM4EMEN1ALDH1A1 | |
| SCHEMBL27581090 | 0.71 | NCF1 (0.43) | SMN1; SMN2PKMMAPK1RXFP1HTT | |
| SCHEMBL6970415 | 0.71 | TUBB4A (0.44) | — | |
| SCHEMBL3966942 | 0.70 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPK1HTTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | ERBB2 4301/4885SMN1; SMN2 3011/4885PKM 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.